Show simple item record

2009-06-16Zeitschriftenartikel DOI: 10.18452/10756
Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting
dc.contributor.authorSørensen, Patricia Diana
dc.contributor.authorJakobsen, Erik Hugger
dc.contributor.authorLangkjer, Sven Tyge
dc.contributor.authorBokmand, Susanne
dc.contributor.authorØstergaard, Birthe
dc.contributor.authorOlsen, Dorte Aalund
dc.contributor.authorMadsen, Jonna Skov
dc.contributor.authorBrandslund, Ivan
dc.date.accessioned2017-06-17T05:26:46Z
dc.date.available2017-06-17T05:26:46Z
dc.date.created2010-07-01
dc.date.issued2009-06-16
dc.identifier.issn1437-4331
dc.identifier.urihttp://edoc.hu-berlin.de/18452/11408
dc.description.abstractBackground: The purpose of this study was to determine the positive predictive value (PPV) of positive serum human epidermal growth factor receptor-2 (HER-2) for monitoring women with breast cancer following diagnosis and treatment in a routine clinical setting. Methods: Serum HER-2 was measured in 1348 patients with breast cancer: 837 during routine oncology clinic visits and 511 following new diagnosis. All patients with positive serum HER-2, 1/5 of negative patients from the oncology clinic, and all the newly diagnosed were followed; a total of 862 patients. Serum HER-2 was measured using the Bayer ADVIA Centaur assay. Tissue HER-2 was determined using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). IHC +3 or IHC +2 and FISH>2.0 were positive. Patients were considered to have positive serum HER-2 when at least two values were >15 ng/mL. Recurrence, progression and regression were diagnosed according to usual clinical practice. Serum HER-2 concentrations did not contribute to diagnostic decision-making or selection of treatment. Results: From January 2004 to January 2009, 149 patients were found to have positive serum HER-2. Of these, 35 were tissue HER-2 positive at surgery, 69 tissue-negative and 45 were not determined. Fifty-five of 149 that were serum HER-2 positive (37%, 95% CI: 29–45) had metastases. Among the 35 tissue-positive patients, 25 had recurrence in the form of metastases and there was good correlation between recurrence/progression and increase in serum HER-2 (p<0.0003). There was also a high correlation between effect of treatment and decline in serum HER-2 (p<0.0003). Of the 69 tissue-negative patients, 29 had recurrence in the form of metastases, and there was good correlation with serum HER-2 levels (p<0.000004). In this routine application of serum HER-2, the PPV for metastases recurrence detection in both tissue-positive and tissue-negative was 54 of 104 (52%, 95% CI: 42%–62%), in tissue-positive 25 of 35 (71%, 95% CI: 54%–85%), in tissue-negative 29 of 69 (42%, 95% CI: 30%–54%). The lead time of increases in serum HER-2 before recurrence could be determined in ten tissue-positive patients was 3–24 months (mean 11.3 months), when compared to standard clinical imaging methods. Conclusions: Serum HER-2 is a useful marker for the detection of recurrence of breast cancer and for monitoring the effect of treatment, especially in tissue HER-2 positive patients. Clin Chem Lab Med 2009;47:1117–23.eng
dc.language.isound
dc.publisherKooperation de Gruyter
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.titleSerum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:11-100132184
dc.identifier.doihttp://dx.doi.org/10.18452/10756
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-year2009
dc.description.versionPeer Reviewed
dcterms.bibliographicCitation.doi10.1515/CCLM.2009.241
dcterms.bibliographicCitation.journaltitleClinical Chemistry and Laboratory Medicine
dcterms.bibliographicCitation.volume47
dcterms.bibliographicCitation.issue9
dcterms.bibliographicCitation.originalpublishernamede Gruyter
dcterms.bibliographicCitation.pagestart1117
dcterms.bibliographicCitation.pageend1123

Show simple item record